Avalo Therapeutics, Inc. (AVTX)
14.41
-1.51
(-9.48%)
USD |
NASDAQ |
Apr 08, 16:00
15.48
+1.07
(+7.43%)
After-Hours: 20:00
Avalo Therapeutics EPS Diluted (Quarterly) : -0.7411 for Dec. 31, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AbbVie, Inc. | 1.018 |
| Corcept Therapeutics, Inc. | 0.1994 |
| Catalyst Pharmaceuticals, Inc. | 0.4136 |
| Relmada Therapeutics, Inc. | -0.2911 |
| Theravance Biopharma, Inc. | 1.150 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -13.72M |
| Revenue (Quarterly) | 0.059M |
| Total Expenses (Quarterly) | 13.78M |
| Enterprise Value | 232.44M |
| Gross Profit Margin (Quarterly) | 72.88% |
| Profit Margin (Quarterly) | -23.25K% |
| Earnings Yield | -46.68% |
| Normalized Earnings Yield | -42.31 |